Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Burak Yasin Aktaş"'
Autor:
Feride Yılmaz, Serkan Yaşar, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Deniz Can Güven, Arif Akyıldız, Elvin Chalabiyev, Burak Yasin Aktaş, Zafer Arık, Mustafa Erman
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC. In the second line, weekly or three-weekly irinotecan regimen
Externí odkaz:
https://doaj.org/article/d05ee6cbcd604c23bdd7f7e674ff535f
Autor:
Burak Yasin Aktaş, Emine Büşra Ata, Engin Çeşmeci, İbrahim Yahya Çakır, Muharrem Coşkunpınar, Yağmur Tahillioğlu, Gürkan Güner, Deniz Can Güven, Zafer Arık, Neyran Kertmen, Ömer Dizdar, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9689-9700 (2023)
Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating anemia in cancer patients, the number of studies reporting the efficacy of iron replacement in
Externí odkaz:
https://doaj.org/article/f55f571aa8f04f59a35f393210fd57cc
Autor:
Burak Yasin Aktaş, Beril Hüseyin, Deniz Yüce, Ömer Dizdar, Mustafa Erman, Mutlu Hayran, İsmail Çelik
Publikováno v:
Archives of Basic and Clinical Research, Vol 5, Iss 1, Pp 178-184 (2023)
Externí odkaz:
https://doaj.org/article/9916d1477db24e7aafb00040c50304bc
Autor:
Metin Demir, Denizcan Güven, Burak Yasin Aktaş, Gürkan Güner, Oktay Halit Aktepe, Hakan Taban, Yusuf Karakaş, Sadettin Kılıçkap, Ayşe Kars, Alev Türker, Ömer Dizdar
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 04, Pp 287-292 (2022)
Objective Liposarcomas are relatively rare tumors. Prognostic and predictive factors and treatment options are limited. We herein presented our 10-year experience with liposarcomas. Materials and Methods Adult patients with liposarcoma treated betwee
Externí odkaz:
https://doaj.org/article/d48e7724c2054aaea29d505e552abdc2
Autor:
Hasan Çağrı Yıldırım, Deniz Can Guven, Oktay Halit Aktepe, Hakan Taban, Feride Yilmaz, Serkan Yasar, Burak Yasin Aktaş, Gürkan Güner, Ömer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap
Background Although the immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. Some of the patients in this group, which is considered to have hyperprogressive disease (HPD), have a shorter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2dee46c5714fde7e79896e59f2cdcb0
https://doi.org/10.21203/rs.3.rs-1184111/v1
https://doi.org/10.21203/rs.3.rs-1184111/v1
